# Passage Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/passage-bio

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.passagebio.com
- Total disclosed funding: $226M
- Latest round: Series B (Aug 21, 2019)
- Investors on record: 11

## About

Established in 2018 and based in Pennsylvania, US, Passage Bio, Inc. operates as a biotechnology company that develops adeno-associated virus (AAV)-delivered therapeutics for the treatment of central nervous system diseases.

## Funding rounds

- Series B, Aug 21, 2019, $110M — Frazier Healthcare Partners, OrbiMed Advisors, Versant Ventures, Vivo Capital, Access Industries, New Leaf Venture Partners, Lilly Asia Ventures, Boxer Capital, Sphera Funds Management, Highline Capital Partners LLP, Logos Capital
- Series A, Feb 14, 2019, $116M — Frazier Healthcare Partners, OrbiMed Advisors, Versant Ventures, Vivo Capital, New Leaf Venture Partners, Lilly Asia Ventures

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Sphera Funds Management — Series B
- Highline Capital Partners LLP — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B